Subscribe
shutterstock_1106804450_penpics_studio
PENpics Studio / Shutterstock.com
5 August 2021GenericsSophie Topham

UK experimental use exemptions: Part 3—the expanded exemption

In the third article of a four-part series on experimental use exemptions from infringement in the UK, we consider the expansion of the original experimental use exemption (Section 60(5)(b) UK Patents Act [UKPA] 1977) introduced by the Legislative Reform (Patents) Order 2014/1997.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver
10 August 2021   In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.
Big Pharma
UK experimental use exemptions: part 1—the original
15 July 2021   In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Europe
UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver
10 August 2021   In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.
Big Pharma
UK experimental use exemptions: part 1—the original
15 July 2021   In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement

More on this story

Europe
UK experimental use exemptions: Part 4—the SPC manufacturing and stockpiling waiver
10 August 2021   In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.
Generics
UK experimental use exemptions: Part 2—the Bolar exemption
22 July 2021   In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.
Big Pharma
UK experimental use exemptions: part 1—the original
15 July 2021   In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement

More features

Life sciences leaders recognised at LSPN Awards USA 2025
AstraZeneca to appeal invalidated diabetes patent in generics dispute
Commercialising genomic tech in Nigeria
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
In vivo cell therapy: A world beyond ex vivo engineering
How pharma should prep for the six-bill avalanche from Congress